SAGE Therapeutics (SAGE) Reports Q1 Net Loss of $122.1M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
May 3, 2022 6:30 AM EDTRolling NDA submission for zuranolone in MDD underway, with full submission expected to be completed in the second half of 2022, associated NDA submission in PPD planned for early 2023
Topline data from Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD on track for mid-2022
Six planned and ongoing Phase 2 studies across neuropsychiatry and neurology franchises, demonstrate focused execution across pipeline programs
Company leadership strengthened with appointment of Mark Pollack, M.D., as Senior Vice President, Medical Affairs
Conference call... More
